To confirm that α-TREM-1 promotes CD177+ neutrophil differentiation in IBD, we examined the CD177+IL-22+ population after α-TREM-1 treatment of neutrophils from healthy controls and IBD patients, with or without LPS and IL-23. Here, IL22 is linked to inflammatory bowel disease.